Zanamivir | Health Canada Patents | Expiry | Expiration | Dates | PharmaCompass.com

Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
Drugs in Dev.
News
Blog
Market Place
Login

Zanamivir
Health Canada Patents

EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

Contact Supplier

SPI Pharma has been solving formulation challenges using superior functional materials.

Contact Supplier

Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

Contact Supplier

Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

Contact Supplier

FAMAR CDMO- From early development to commercial manufacturing.

Contact Supplier

Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

Contact Supplier

Zanamivir

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

2 API Suppliers, 1 NDC API, 2 Listed Suppliers

2 API Suppliers
1 NDC API
2 Listed Suppliers

FINISHED DOSAGE FORMULATIONS

6 FDF Dossiers, 1 FDA Orange Book, 3 Europe, 1 Canada, 1 South Africa

6 FDF Dossiers
1 FDA Orange Book
3 Europe
1 Canada
1 South Africa

RELATED EXCIPIENT COMPANIES

2 BASF, 3 Kerry, 1 Roquette

2 BASF
3 Kerry
1 Roquette

EXCIPIENTS BY APPLICATIONS

3 Co-Processed Excipients, 2 Granulation, 2 Direct Compression, 1 Fillers, Diluents & Binders, 1 Coating Systems & Additives, 1 Controlled & Modified Release

3 Co-Processed Excipients
2 Granulation
2 Direct Compression
1 Fillers, Diluents & Binders
1 Coating Systems & Additives
1 Controlled & Modified Release

DIGITAL CONTENT

1 DATA COMPILATION #PharmaFlow, 8 NEWS #PharmaBuzz

1 DATA COMPILATION #PharmaFlow
8 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

1 US Medicaid Prescriptions, 2 Finished Drug Prices

1 US Medicaid Prescriptions
2 Finished Drug Prices

MARKET PLACE

1 APIs, 1 EXCIPIENTS

1 APIs
1 EXCIPIENTS

PATENTS & EXCLUSIVITIES

3 Health Canada Patents

3 Health Canada Patents

REF. STANDARDS & IMPURITIES

3 USP, 3 Others

3 USP
3 Others

Xls

Filters

Reset all filters

Filters

FILTER :

filter Company Reset all filters

3 All

01 3GlaxoSmithKline Inc.

filter Patent Reset all filters

3 All

01 12081356

02 12177990

03 12291994

filter Product Reset all filters

3 All

01 3Zanamivir

filter Dosage Reset all filters

3 All

01 3Dry Powder Inhaler

filter Exp Date Reset all filters

3 All

01 22011-04-24

02 12014-12-15

Product Main Page

01

GlaxoSmithKline Inc.

Zanamivir

BioAsia

Not Confirmed

GlaxoSmithKline Inc.

BioAsia

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2011-04-24

Date Granted : 2003-10-14

Brand Name : RELENZA

Patent Number : 2291994

Filing Date : 1991-04-24

Strength per Unit : 5mg/blister

Dosage Form : Dry Powder Inhaler

Human Or VET : Human

Route of Administration : Oral Inhalation

Patent Expiration Date : 2011-04-24

Date Granted : 2003-10-14

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

02

GlaxoSmithKline Inc.

Zanamivir

BioAsia

Not Confirmed

GlaxoSmithKline Inc.

BioAsia

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2011-04-24

Date Granted : 2000-02-22

Brand Name : RELENZA

Patent Number : 2081356

Filing Date : 1991-04-24

Strength per Unit : 5mg/blister

Dosage Form : Dry Powder Inhaler

Human Or VET : Human

Route of Administration : Oral Inhalation

Patent Expiration Date : 2011-04-24

Date Granted : 2000-02-22

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

03

GlaxoSmithKline Inc.

Zanamivir

BioAsia

Not Confirmed

GlaxoSmithKline Inc.

BioAsia

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2014-12-15

Date Granted : 2000-04-25

Brand Name : RELENZA

Patent Number : 2177990

Filing Date : 1994-12-15

Strength per Unit : 5mg/blister

Dosage Form : Dry Powder Inhaler

Human Or VET : Human

Route of Administration : Oral Inhalation

Patent Expiration Date : 2014-12-15

Date Granted : 2000-04-25

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
ASK US!